143 related articles for article (PubMed ID: 19461179)
1. [Effect of withdrawal of 5-fluorouracil bolus administration on recovery from neutropenia in colorectal cancer patients treated with mFOLFOX6 chemotherapy-comparison with total dosage reduction].
Ueda H; Demizu M; Oosawa M; Chihara S; Nakanishi Y; Maeda C; Yano K; Kimura F; Iwakawa S
Gan To Kagaku Ryoho; 2009 May; 36(5):789-93. PubMed ID: 19461179
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
[TBL] [Abstract][Full Text] [Related]
5. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
Wang WS; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chiou TJ; Liu JH; Yen CC; Chen PM
Oncologist; 2007 Mar; 12(3):312-9. PubMed ID: 17405895
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study.
Matsumoto S; Nishimura T; Kanai M; Mori Y; Nagayama S; Kawamura J; Nomura A; Miyamoto S; Kitano T; Ishiguro H; Yanagihara K; Teramukai S; Sakai Y; Chiba T; Fukushima M
Chemotherapy; 2008; 54(5):395-403. PubMed ID: 18781065
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of modified FOLFOX6 regimen in aged patients with nonresectable colorectal cancer].
Ishiguro T; Ishibashi K; Okada N; Kuwabara K; Miyazaki T; Yokoyama M; Matsuki M; Sano M; Inoue N; Ishida H
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2286-8. PubMed ID: 19106598
[TBL] [Abstract][Full Text] [Related]
8. Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
Siegel-Lakhai WS; Beijnen JH; Vervenne WL; Boot H; Keessen M; Versola M; Koch KM; Smith DA; Pandite L; Richel DJ; Schellens JH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4495-502. PubMed ID: 17671135
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
[TBL] [Abstract][Full Text] [Related]
10. [A case of recurrent rectal cancer with lymphangiosis carcinomatosa successfully treated with modified FOLFOX6 therapy].
Furuta R; Ina K; Kataoka T; Nagao S; Kayukawa S; Mori F; Masaki A; Ando T; Goto H
Gan To Kagaku Ryoho; 2008 May; 35(5):849-52. PubMed ID: 18487928
[TBL] [Abstract][Full Text] [Related]
11. [10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer].
Zhang HG; Cai RG; Chen SS; Wu F; Chu DT
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1462-4. PubMed ID: 17785082
[TBL] [Abstract][Full Text] [Related]
12. [Safety and efficacy analysis of FOLFOX4 regimen in elderly compared to younger colorectal cancer patients].
Kuboki Y; Ichimura T; Ogura M; Matsuda M; Suenaga M; Shinozaki E; Matsuzaka S; Chin K; Mizunuma N; Hatake K
Gan To Kagaku Ryoho; 2008 May; 35(5):781-5. PubMed ID: 18487913
[TBL] [Abstract][Full Text] [Related]
13. Influence of high-dose leucovorin and 5-fluorouracil chemotherapy regimen on P wave duration and dispersion.
Ceyhan C; Meydan N; Barutca S; Tekten T; Onbasili AO; Ozturk B; Unal S; Bayrak I
J Clin Pharm Ther; 2004 Jun; 29(3):267-71. PubMed ID: 15153089
[TBL] [Abstract][Full Text] [Related]
14. [The prognosis of patients with an allergic reaction in the treatment of mFOLFOX6 therapy].
Okada N; Ishibashi K; Kuwabara K; Ishiguro T; Hatano S; Hokama N; Tajima Y; Ishii M; Kubota S; Chika N; Miyazaki T; Ishida H
Gan To Kagaku Ryoho; 2009 Nov; 36(12):1985-7. PubMed ID: 20037299
[TBL] [Abstract][Full Text] [Related]
15. [Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen].
Kato T; Matsunaga Y; Motokawa S; Nakagaki S; Nagata N; Yoshida T; Muramatsu T; Kimura H; Ohashi Y; Kudou Y; Shino M; Yamazaki K; Boku N
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1697-702. PubMed ID: 19838030
[TBL] [Abstract][Full Text] [Related]
16. [FOLFOX].
Mishima H; Ikenaga M; Tsujinaka T; Yasui M; Kashiwazaki M; Miyazaki M; Hirao M; Fujitani K; Nakamori S
Gan To Kagaku Ryoho; 2006 Jul; 33(7):911-4. PubMed ID: 16835479
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
18. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
[TBL] [Abstract][Full Text] [Related]
19. [A case of rectal cancer with liver metastases successfully treated with modified FOLFOX6 therapy].
Shoji T; Takahashi Y; Matsuda I; Suzuki K; Misumi K; Taniguchi M; Yamazaki M; Yonekawa H
Gan To Kagaku Ryoho; 2009 Sep; 36(9):1579-81. PubMed ID: 19755838
[TBL] [Abstract][Full Text] [Related]
20. 5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity.
Jensen SA; Sørensen JB
Cancer Chemother Pharmacol; 2012 Jan; 69(1):57-64. PubMed ID: 21603868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
